ºÝºÝߣshows by User: drmazenzoubi / http://www.slideshare.net/images/logo.gif ºÝºÝߣshows by User: drmazenzoubi / Wed, 20 Nov 2024 05:34:51 GMT ºÝºÝߣShare feed for ºÝºÝߣshows by User: drmazenzoubi Unveiling Psoriatic Arthritis and the Transformative Role of Guselkumab in Treatment.pptx /slideshow/unveiling-psoriatic-arthritis-and-the-transformative-role-of-guselkumab-in-treatment-pptx/273455803 tremfya1-241120053451-b56f7d0c
Unveiling Psoriatic Arthritis and the Transformative Role of Guselkumab in Treatment delves into the complexities of psoriatic arthritis (PsA) and highlights the groundbreaking advancements in its management with guselkumab, an innovative IL-23 inhibitor. This presentation offers: A concise overview of PsA pathophysiology and its impact on patients' lives. Insight into the latest clinical trial data and evidence supporting guselkumab’s efficacy and safety. Comparative analysis of guselkumab with traditional therapies. A glimpse into personalized treatment strategies leveraging IL-23 inhibition. Ideal for healthcare professionals, rheumatologists, and researchers, this presentation synthesizes cutting-edge findings to illuminate the path forward in PsA care.]]>
Unveiling Psoriatic Arthritis and the Transformative Role of Guselkumab in Treatment delves into the complexities of psoriatic arthritis (PsA) and highlights the groundbreaking advancements in its management with guselkumab, an innovative IL-23 inhibitor. This presentation offers: A concise overview of PsA pathophysiology and its impact on patients' lives. Insight into the latest clinical trial data and evidence supporting guselkumab’s efficacy and safety. Comparative analysis of guselkumab with traditional therapies. A glimpse into personalized treatment strategies leveraging IL-23 inhibition. Ideal for healthcare professionals, rheumatologists, and researchers, this presentation synthesizes cutting-edge findings to illuminate the path forward in PsA care.]]> Wed, 20 Nov 2024 05:34:51 GMT /slideshow/unveiling-psoriatic-arthritis-and-the-transformative-role-of-guselkumab-in-treatment-pptx/273455803 drmazenzoubi@slideshare.net(drmazenzoubi) Unveiling Psoriatic Arthritis and the Transformative Role of Guselkumab in Treatment.pptx drmazenzoubi Unveiling Psoriatic Arthritis and the Transformative Role of Guselkumab in Treatment delves into the complexities of psoriatic arthritis (PsA) and highlights the groundbreaking advancements in its management with guselkumab, an innovative IL-23 inhibitor. This presentation offers: A concise overview of PsA pathophysiology and its impact on patients' lives. Insight into the latest clinical trial data and evidence supporting guselkumab’s efficacy and safety. Comparative analysis of guselkumab with traditional therapies. A glimpse into personalized treatment strategies leveraging IL-23 inhibition. Ideal for healthcare professionals, rheumatologists, and researchers, this presentation synthesizes cutting-edge findings to illuminate the path forward in PsA care. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/tremfya1-241120053451-b56f7d0c-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Unveiling Psoriatic Arthritis and the Transformative Role of Guselkumab in Treatment delves into the complexities of psoriatic arthritis (PsA) and highlights the groundbreaking advancements in its management with guselkumab, an innovative IL-23 inhibitor. This presentation offers: A concise overview of PsA pathophysiology and its impact on patients&#39; lives. Insight into the latest clinical trial data and evidence supporting guselkumab’s efficacy and safety. Comparative analysis of guselkumab with traditional therapies. A glimpse into personalized treatment strategies leveraging IL-23 inhibition. Ideal for healthcare professionals, rheumatologists, and researchers, this presentation synthesizes cutting-edge findings to illuminate the path forward in PsA care.
Unveiling Psoriatic Arthritis and the Transformative Role of Guselkumab in Treatment.pptx from Mazin Al Zo'ubi
]]> 75 0 https://cdn.slidesharecdn.com/ss_thumbnails/tremfya1-241120053451-b56f7d0c-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 The Role of TNF Inhibitors in Managing Psoriatic Arthritis:�Focus on Golimumab /slideshow/the-role-of-tnf-inhibitors-in-managing-psoriatic-arthritis-focus-on-golimumab/272123716 golden-241001093214-3a69feb5
In this presentation, we aim to achieve several key objectives: First, we will provide an overview of psoriatic arthritis. Next, we will delve into the role of TNF inhibitors in the management of psoriatic arthritis, with a particular focus on Golimumab and its effectiveness. Finally, we will illustrate these points with a detailed case study, following a patient from initial presentation through to remission.]]>
In this presentation, we aim to achieve several key objectives: First, we will provide an overview of psoriatic arthritis. Next, we will delve into the role of TNF inhibitors in the management of psoriatic arthritis, with a particular focus on Golimumab and its effectiveness. Finally, we will illustrate these points with a detailed case study, following a patient from initial presentation through to remission.]]> Tue, 01 Oct 2024 09:32:14 GMT /slideshow/the-role-of-tnf-inhibitors-in-managing-psoriatic-arthritis-focus-on-golimumab/272123716 drmazenzoubi@slideshare.net(drmazenzoubi) The Role of TNF Inhibitors in Managing Psoriatic Arthritis:�Focus on Golimumab drmazenzoubi In this presentation, we aim to achieve several key objectives: First, we will provide an overview of psoriatic arthritis. Next, we will delve into the role of TNF inhibitors in the management of psoriatic arthritis, with a particular focus on Golimumab and its effectiveness. Finally, we will illustrate these points with a detailed case study, following a patient from initial presentation through to remission. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/golden-241001093214-3a69feb5-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> In this presentation, we aim to achieve several key objectives: First, we will provide an overview of psoriatic arthritis. Next, we will delve into the role of TNF inhibitors in the management of psoriatic arthritis, with a particular focus on Golimumab and its effectiveness. Finally, we will illustrate these points with a detailed case study, following a patient from initial presentation through to remission.
The Role of TNF Inhibitors in Managing Psoriatic Arthritis: Focus on Golimumab from Mazin Al Zo'ubi
]]> 18 0 https://cdn.slidesharecdn.com/ss_thumbnails/golden-241001093214-3a69feb5-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Empowering Physicians: Unveiling the Mysteries of Systemic Lupus Erythematosus /slideshow/empowering-physicians-unveiling-the-mysteries-of-systemic-lupus-erythematosus/272011600 burjeelawarnessmeeting3-240925102419-2d8c86dd
Understanding Pathogenesis, Epidemiology, Clinical Manifestations, Diagnosis, and Management. Focusing on Saphnelo role in lupus.]]>
Understanding Pathogenesis, Epidemiology, Clinical Manifestations, Diagnosis, and Management. Focusing on Saphnelo role in lupus.]]> Wed, 25 Sep 2024 10:24:19 GMT /slideshow/empowering-physicians-unveiling-the-mysteries-of-systemic-lupus-erythematosus/272011600 drmazenzoubi@slideshare.net(drmazenzoubi) Empowering Physicians: Unveiling the Mysteries of Systemic Lupus Erythematosus drmazenzoubi Understanding Pathogenesis, Epidemiology, Clinical Manifestations, Diagnosis, and Management. Focusing on Saphnelo role in lupus. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/burjeelawarnessmeeting3-240925102419-2d8c86dd-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Understanding Pathogenesis, Epidemiology, Clinical Manifestations, Diagnosis, and Management. Focusing on Saphnelo role in lupus.
Empowering Physicians: Unveiling the Mysteries of Systemic Lupus Erythematosus from Mazin Al Zo'ubi
]]> 17 0 https://cdn.slidesharecdn.com/ss_thumbnails/burjeelawarnessmeeting3-240925102419-2d8c86dd-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Interstitial Lung Disease​ /slideshow/interstitial-lung-disease-254850546/254850546 ild-221210152505-6527ceef
Interstitial Lung Disease​ presentation, classification, and management]]>
Interstitial Lung Disease​ presentation, classification, and management]]> Sat, 10 Dec 2022 15:25:05 GMT /slideshow/interstitial-lung-disease-254850546/254850546 drmazenzoubi@slideshare.net(drmazenzoubi) Interstitial Lung Disease​ drmazenzoubi Interstitial Lung Disease​ presentation, classification, and management <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ild-221210152505-6527ceef-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Interstitial Lung Disease​ presentation, classification, and management
Interstitial Lung Disease​ from Mazin Al Zo'ubi
]]> 1896 0 https://cdn.slidesharecdn.com/ss_thumbnails/ild-221210152505-6527ceef-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 VTE and PHTN.pptx /slideshow/vte-and-phtnpptx/254728483 vteandphtn-221204175605-7738d694
Venous Thromboembolism and Pulmonary Hypertension]]>
Venous Thromboembolism and Pulmonary Hypertension]]> Sun, 04 Dec 2022 17:56:04 GMT /slideshow/vte-and-phtnpptx/254728483 drmazenzoubi@slideshare.net(drmazenzoubi) VTE and PHTN.pptx drmazenzoubi Venous Thromboembolism and Pulmonary Hypertension <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/vteandphtn-221204175605-7738d694-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Venous Thromboembolism and Pulmonary Hypertension
VTE and PHTN.pptx from Mazin Al Zo'ubi
]]> 40 0 https://cdn.slidesharecdn.com/ss_thumbnails/vteandphtn-221204175605-7738d694-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 COPD.pptx /slideshow/copdpptx-254728443/254728443 copd-221204175239-a3fb7e81
Chronic Obstructive Pulmonary Disease]]>
Chronic Obstructive Pulmonary Disease]]> Sun, 04 Dec 2022 17:52:38 GMT /slideshow/copdpptx-254728443/254728443 drmazenzoubi@slideshare.net(drmazenzoubi) COPD.pptx drmazenzoubi Chronic Obstructive Pulmonary Disease <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/copd-221204175239-a3fb7e81-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Chronic Obstructive Pulmonary Disease
COPD.pptx from Mazin Al Zo'ubi
]]> 58 0 https://cdn.slidesharecdn.com/ss_thumbnails/copd-221204175239-a3fb7e81-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Conventional radiography in Rheumatic diseases /drmazenzoubi/conventional-radiography-in-rheumatic-diseases conventionalradiography-200702182859
Describing radiological findings of rheumatic disease in conventional radiography]]>
Describing radiological findings of rheumatic disease in conventional radiography]]> Thu, 02 Jul 2020 18:28:59 GMT /drmazenzoubi/conventional-radiography-in-rheumatic-diseases drmazenzoubi@slideshare.net(drmazenzoubi) Conventional radiography in Rheumatic diseases drmazenzoubi Describing radiological findings of rheumatic disease in conventional radiography <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/conventionalradiography-200702182859-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Describing radiological findings of rheumatic disease in conventional radiography
Conventional radiography in Rheumatic diseases from Mazin Al Zo'ubi
]]> 305 0 https://cdn.slidesharecdn.com/ss_thumbnails/conventionalradiography-200702182859-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital /slideshow/risk-factors-of-acute-coronary-syndrome-at-prince-ali-bin-alhussein-hospital/123024257 intjmiv4n2p0en-181114190356
Objective:The aim of this survey to identify the relationship between ACS and its risk factors and the association between the risks factors themselves. Method: A retrospective study depends on the registered files of the admitted patients to Prince Ali Bin Alhussein hospital with ACS since April 2013 till October of 2013 included 174 patients. Result:The above mentioned data and results show a strong relationship between ACS and the mentioned risk factors. Conclusion: There is a strong relationship between risks factors themselves as D.M and hypertension, and between hypertension with the sex and smoking.There's an association between D.M and the patient's gender]]>
Objective:The aim of this survey to identify the relationship between ACS and its risk factors and the association between the risks factors themselves. Method: A retrospective study depends on the registered files of the admitted patients to Prince Ali Bin Alhussein hospital with ACS since April 2013 till October of 2013 included 174 patients. Result:The above mentioned data and results show a strong relationship between ACS and the mentioned risk factors. Conclusion: There is a strong relationship between risks factors themselves as D.M and hypertension, and between hypertension with the sex and smoking.There's an association between D.M and the patient's gender]]> Wed, 14 Nov 2018 19:03:56 GMT /slideshow/risk-factors-of-acute-coronary-syndrome-at-prince-ali-bin-alhussein-hospital/123024257 drmazenzoubi@slideshare.net(drmazenzoubi) Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital drmazenzoubi Objective:The aim of this survey to identify the relationship between ACS and its risk factors and the association between the risks factors themselves. Method: A retrospective study depends on the registered files of the admitted patients to Prince Ali Bin Alhussein hospital with ACS since April 2013 till October of 2013 included 174 patients. Result:The above mentioned data and results show a strong relationship between ACS and the mentioned risk factors. Conclusion: There is a strong relationship between risks factors themselves as D.M and hypertension, and between hypertension with the sex and smoking.There's an association between D.M and the patient's gender <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/intjmiv4n2p0en-181114190356-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Objective:The aim of this survey to identify the relationship between ACS and its risk factors and the association between the risks factors themselves. Method: A retrospective study depends on the registered files of the admitted patients to Prince Ali Bin Alhussein hospital with ACS since April 2013 till October of 2013 included 174 patients. Result:The above mentioned data and results show a strong relationship between ACS and the mentioned risk factors. Conclusion: There is a strong relationship between risks factors themselves as D.M and hypertension, and between hypertension with the sex and smoking.There&#39;s an association between D.M and the patient&#39;s gender
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital from Mazin Al Zo'ubi
]]> 61 1 https://cdn.slidesharecdn.com/ss_thumbnails/intjmiv4n2p0en-181114190356-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 TOPICAL MINOXIDIL 5% INDUCED MALE SEXUAL DYSFUNCTION /slideshow/topical-minoxidil-5-induced-male-sexual-dysfunction/123023086 5-181114185304
Minoxidil is an antihypertensive vasodilator medication. It also slows or stops hair loss and promotes hair regrowth in some people. The exact way that this medicine works is not known. If hair growth is going to occur with the use of minoxidil, it usually occurs after the medicine has been used for several months and lasts only if the medicine continues to be used. Hair loss will begin again within a few months after minoxidil treatment is stopped. Adverse reactions include irritation of the skin, itching, contact dermatitis, and dryness of the scalp or flaking. An increase in the absorption of minoxidil from the scalp can occur in patients with damaged skin, leading to increased side effects. Minoxidil may cause serious side effects, including unwanted facial/body hair, dizziness, fast/irregular heartbeat, fainting, chest pain, swelling of hands/feet, unusual weight gain, tiredness, difficulty breathing especially when lying down. Erectile dysfunction (impotence) is the inability to get and keep an erection firm enough for sex. Erectile dysfunction can be caused by Physical causes, Hormonal disorders, Structural/anatomical disorder, drugs induced, and Psychological causes. We report a case of erectile dysfunction in a young patient not known to have any medical illness. In the view of unyielding clinical and laboratory evaluation, a druginduced erectile dysfunction and decreased libido were suspected. Because of the use of topical minoxidil 5% over the last 4 months, and the improvement of the patient's condition, including palpitation, chest tightness, dizziness, and erectile dysfunction and libido after discontinuation of topical minoxidil 5%, and the recurrence of symptoms following it's re-administration, and after ruling out organic and psychogenic causes, we concluded that topical minoxidil 5% was the cause of the patient's clinical picture and should be considered as a cause of unexplained erectile dysfunction and decrease libido.]]>
Minoxidil is an antihypertensive vasodilator medication. It also slows or stops hair loss and promotes hair regrowth in some people. The exact way that this medicine works is not known. If hair growth is going to occur with the use of minoxidil, it usually occurs after the medicine has been used for several months and lasts only if the medicine continues to be used. Hair loss will begin again within a few months after minoxidil treatment is stopped. Adverse reactions include irritation of the skin, itching, contact dermatitis, and dryness of the scalp or flaking. An increase in the absorption of minoxidil from the scalp can occur in patients with damaged skin, leading to increased side effects. Minoxidil may cause serious side effects, including unwanted facial/body hair, dizziness, fast/irregular heartbeat, fainting, chest pain, swelling of hands/feet, unusual weight gain, tiredness, difficulty breathing especially when lying down. Erectile dysfunction (impotence) is the inability to get and keep an erection firm enough for sex. Erectile dysfunction can be caused by Physical causes, Hormonal disorders, Structural/anatomical disorder, drugs induced, and Psychological causes. We report a case of erectile dysfunction in a young patient not known to have any medical illness. In the view of unyielding clinical and laboratory evaluation, a druginduced erectile dysfunction and decreased libido were suspected. Because of the use of topical minoxidil 5% over the last 4 months, and the improvement of the patient's condition, including palpitation, chest tightness, dizziness, and erectile dysfunction and libido after discontinuation of topical minoxidil 5%, and the recurrence of symptoms following it's re-administration, and after ruling out organic and psychogenic causes, we concluded that topical minoxidil 5% was the cause of the patient's clinical picture and should be considered as a cause of unexplained erectile dysfunction and decrease libido.]]> Wed, 14 Nov 2018 18:53:04 GMT /slideshow/topical-minoxidil-5-induced-male-sexual-dysfunction/123023086 drmazenzoubi@slideshare.net(drmazenzoubi) TOPICAL MINOXIDIL 5% INDUCED MALE SEXUAL DYSFUNCTION drmazenzoubi Minoxidil is an antihypertensive vasodilator medication. It also slows or stops hair loss and promotes hair regrowth in some people. The exact way that this medicine works is not known. If hair growth is going to occur with the use of minoxidil, it usually occurs after the medicine has been used for several months and lasts only if the medicine continues to be used. Hair loss will begin again within a few months after minoxidil treatment is stopped. Adverse reactions include irritation of the skin, itching, contact dermatitis, and dryness of the scalp or flaking. An increase in the absorption of minoxidil from the scalp can occur in patients with damaged skin, leading to increased side effects. Minoxidil may cause serious side effects, including unwanted facial/body hair, dizziness, fast/irregular heartbeat, fainting, chest pain, swelling of hands/feet, unusual weight gain, tiredness, difficulty breathing especially when lying down. Erectile dysfunction (impotence) is the inability to get and keep an erection firm enough for sex. Erectile dysfunction can be caused by Physical causes, Hormonal disorders, Structural/anatomical disorder, drugs induced, and Psychological causes. We report a case of erectile dysfunction in a young patient not known to have any medical illness. In the view of unyielding clinical and laboratory evaluation, a druginduced erectile dysfunction and decreased libido were suspected. Because of the use of topical minoxidil 5% over the last 4 months, and the improvement of the patient's condition, including palpitation, chest tightness, dizziness, and erectile dysfunction and libido after discontinuation of topical minoxidil 5%, and the recurrence of symptoms following it's re-administration, and after ruling out organic and psychogenic causes, we concluded that topical minoxidil 5% was the cause of the patient's clinical picture and should be considered as a cause of unexplained erectile dysfunction and decrease libido. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/5-181114185304-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Minoxidil is an antihypertensive vasodilator medication. It also slows or stops hair loss and promotes hair regrowth in some people. The exact way that this medicine works is not known. If hair growth is going to occur with the use of minoxidil, it usually occurs after the medicine has been used for several months and lasts only if the medicine continues to be used. Hair loss will begin again within a few months after minoxidil treatment is stopped. Adverse reactions include irritation of the skin, itching, contact dermatitis, and dryness of the scalp or flaking. An increase in the absorption of minoxidil from the scalp can occur in patients with damaged skin, leading to increased side effects. Minoxidil may cause serious side effects, including unwanted facial/body hair, dizziness, fast/irregular heartbeat, fainting, chest pain, swelling of hands/feet, unusual weight gain, tiredness, difficulty breathing especially when lying down. Erectile dysfunction (impotence) is the inability to get and keep an erection firm enough for sex. Erectile dysfunction can be caused by Physical causes, Hormonal disorders, Structural/anatomical disorder, drugs induced, and Psychological causes. We report a case of erectile dysfunction in a young patient not known to have any medical illness. In the view of unyielding clinical and laboratory evaluation, a druginduced erectile dysfunction and decreased libido were suspected. Because of the use of topical minoxidil 5% over the last 4 months, and the improvement of the patient&#39;s condition, including palpitation, chest tightness, dizziness, and erectile dysfunction and libido after discontinuation of topical minoxidil 5%, and the recurrence of symptoms following it&#39;s re-administration, and after ruling out organic and psychogenic causes, we concluded that topical minoxidil 5% was the cause of the patient&#39;s clinical picture and should be considered as a cause of unexplained erectile dysfunction and decrease libido.
TOPICAL MINOXIDIL 5% INDUCED MALE SEXUAL DYSFUNCTION from Mazin Al Zo'ubi
]]> 1413 3 https://cdn.slidesharecdn.com/ss_thumbnails/5-181114185304-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Factors that affect the Quality of Life of Patients with Behcet's Disease /slideshow/factors-that-affect-the-quality-of-life-of-patients-with-behcets-disease/123021053 qol-181114183123
Objective: To assess the quality of life in patients with Behçet's disease, and to address the factors impact the domains of Quality of Life. Methods: We surveyed101 patients with Behcet's disease no less than 3 months before the study. Data were collected using Short Form 36 Quality of life Scale. Results: The quality of life scores in patients with Behçet's disease were low and were adversely influenced by socio-demographic characteristics such as gender, age, work status and education status. Furthermore, disease manifestations such as oral and genital ulcerations, arthritis, and skin lesions affected the quality of life scores. Moreover, patients who experienced pain, poor sleep and fatigue lower the quality of life scale and patients whose social relations were influenced by the disease had significantly lower the quality of life scores. Conclusion: Patients with Behcet's disease reported a low level of quality of life. Keywords: Behcet's disease, Factors affecting, Quality of life, Jordan.]]>
Objective: To assess the quality of life in patients with Behçet's disease, and to address the factors impact the domains of Quality of Life. Methods: We surveyed101 patients with Behcet's disease no less than 3 months before the study. Data were collected using Short Form 36 Quality of life Scale. Results: The quality of life scores in patients with Behçet's disease were low and were adversely influenced by socio-demographic characteristics such as gender, age, work status and education status. Furthermore, disease manifestations such as oral and genital ulcerations, arthritis, and skin lesions affected the quality of life scores. Moreover, patients who experienced pain, poor sleep and fatigue lower the quality of life scale and patients whose social relations were influenced by the disease had significantly lower the quality of life scores. Conclusion: Patients with Behcet's disease reported a low level of quality of life. Keywords: Behcet's disease, Factors affecting, Quality of life, Jordan.]]> Wed, 14 Nov 2018 18:31:23 GMT /slideshow/factors-that-affect-the-quality-of-life-of-patients-with-behcets-disease/123021053 drmazenzoubi@slideshare.net(drmazenzoubi) Factors that affect the Quality of Life of Patients with Behcet's Disease drmazenzoubi Objective: To assess the quality of life in patients with Behçet's disease, and to address the factors impact the domains of Quality of Life. Methods: We surveyed101 patients with Behcet's disease no less than 3 months before the study. Data were collected using Short Form 36 Quality of life Scale. Results: The quality of life scores in patients with Behçet's disease were low and were adversely influenced by socio-demographic characteristics such as gender, age, work status and education status. Furthermore, disease manifestations such as oral and genital ulcerations, arthritis, and skin lesions affected the quality of life scores. Moreover, patients who experienced pain, poor sleep and fatigue lower the quality of life scale and patients whose social relations were influenced by the disease had significantly lower the quality of life scores. Conclusion: Patients with Behcet's disease reported a low level of quality of life. Keywords: Behcet's disease, Factors affecting, Quality of life, Jordan. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/qol-181114183123-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Objective: To assess the quality of life in patients with Behçet&#39;s disease, and to address the factors impact the domains of Quality of Life. Methods: We surveyed101 patients with Behcet&#39;s disease no less than 3 months before the study. Data were collected using Short Form 36 Quality of life Scale. Results: The quality of life scores in patients with Behçet&#39;s disease were low and were adversely influenced by socio-demographic characteristics such as gender, age, work status and education status. Furthermore, disease manifestations such as oral and genital ulcerations, arthritis, and skin lesions affected the quality of life scores. Moreover, patients who experienced pain, poor sleep and fatigue lower the quality of life scale and patients whose social relations were influenced by the disease had significantly lower the quality of life scores. Conclusion: Patients with Behcet&#39;s disease reported a low level of quality of life. Keywords: Behcet&#39;s disease, Factors affecting, Quality of life, Jordan.
Factors that affect the Quality of Life of Patients with Behcet's Disease from Mazin Al Zo'ubi
]]> 88 1 https://cdn.slidesharecdn.com/ss_thumbnails/qol-181114183123-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Managing co morbidities of inflammatory arthritis /slideshow/managing-co-morbidities-of-inflammatory-arthritis/92359524 managingco-morbiditiesofinflammatoryarthritis-180329205922
Managing comorbidities of inflammatory arthritis]]>
Managing comorbidities of inflammatory arthritis]]> Thu, 29 Mar 2018 20:59:22 GMT /slideshow/managing-co-morbidities-of-inflammatory-arthritis/92359524 drmazenzoubi@slideshare.net(drmazenzoubi) Managing co morbidities of inflammatory arthritis drmazenzoubi Managing comorbidities of inflammatory arthritis <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/managingco-morbiditiesofinflammatoryarthritis-180329205922-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Managing comorbidities of inflammatory arthritis
Managing co morbidities of inflammatory arthritis from Mazin Al Zo'ubi
]]> 72 1 https://cdn.slidesharecdn.com/ss_thumbnails/managingco-morbiditiesofinflammatoryarthritis-180329205922-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Ra updates(xaljanz) /slideshow/ra-updatesxaljanz/92359363 raupdatesxaljanz-180329205707
rheumatoid arthritis]]>
rheumatoid arthritis]]> Thu, 29 Mar 2018 20:57:07 GMT /slideshow/ra-updatesxaljanz/92359363 drmazenzoubi@slideshare.net(drmazenzoubi) Ra updates(xaljanz) drmazenzoubi rheumatoid arthritis <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/raupdatesxaljanz-180329205707-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> rheumatoid arthritis
Ra updates(xaljanz) from Mazin Al Zo'ubi
]]> 482 1 https://cdn.slidesharecdn.com/ss_thumbnails/raupdatesxaljanz-180329205707-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 GCA treatment /slideshow/gca-treatment/92358828 gcarx-180329204950
giant cell arteritis treatment]]>
giant cell arteritis treatment]]> Thu, 29 Mar 2018 20:49:50 GMT /slideshow/gca-treatment/92358828 drmazenzoubi@slideshare.net(drmazenzoubi) GCA treatment drmazenzoubi giant cell arteritis treatment <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/gcarx-180329204950-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> giant cell arteritis treatment
GCA treatment from Mazin Al Zo'ubi
]]> 154 1 https://cdn.slidesharecdn.com/ss_thumbnails/gcarx-180329204950-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 GCA /drmazenzoubi/gca-92358759 gca-180329204849
giant cell arteritis]]>
giant cell arteritis]]> Thu, 29 Mar 2018 20:48:49 GMT /drmazenzoubi/gca-92358759 drmazenzoubi@slideshare.net(drmazenzoubi) GCA drmazenzoubi giant cell arteritis <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/gca-180329204849-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> giant cell arteritis
GCA from Mazin Al Zo'ubi
]]> 3553 5 https://cdn.slidesharecdn.com/ss_thumbnails/gca-180329204849-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Fever& pancytopenia /slideshow/fever-pancytopenia/92358642 feverpancytopenia-180329204704
SLE]]>
SLE]]> Thu, 29 Mar 2018 20:47:04 GMT /slideshow/fever-pancytopenia/92358642 drmazenzoubi@slideshare.net(drmazenzoubi) Fever& pancytopenia drmazenzoubi SLE <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/feverpancytopenia-180329204704-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> SLE
Fever& pancytopenia from Mazin Al Zo'ubi
]]> 35 1 https://cdn.slidesharecdn.com/ss_thumbnails/feverpancytopenia-180329204704-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-drmazenzoubi-48x48.jpg?cb=1732080127 www.researchgate.net/profile/Mazen_Al_Zoubi https://cdn.slidesharecdn.com/ss_thumbnails/tremfya1-241120053451-b56f7d0c-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/unveiling-psoriatic-arthritis-and-the-transformative-role-of-guselkumab-in-treatment-pptx/273455803 Unveiling Psoriatic Ar... https://cdn.slidesharecdn.com/ss_thumbnails/golden-241001093214-3a69feb5-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/the-role-of-tnf-inhibitors-in-managing-psoriatic-arthritis-focus-on-golimumab/272123716 The Role of TNF Inhibi... https://cdn.slidesharecdn.com/ss_thumbnails/burjeelawarnessmeeting3-240925102419-2d8c86dd-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/empowering-physicians-unveiling-the-mysteries-of-systemic-lupus-erythematosus/272011600 Empowering Physicians:...